On October 6, 2025, Harrow Health, Inc. announced that it has appointed Frank Mullery as Chief Executive Officer of its wholly‑owned subsidiary ImprimisRx and Bridseida Cruz as Head of Quality. ImprimisRx is a national leader in ophthalmic compounding, providing a critical supply of affordable eye care products to more than 10,000 eye care professionals across the United States.
Frank Mullery brings over 20 years of leadership experience in the healthcare and pharmaceutical industries. He previously served as President of Sintetica US, where he launched the company’s U.S. subsidiary and brought five sterile injectable products to market, and as President and Chief Commercial Officer of STI Pharma, where he oversaw all operations and launched several sterile injectable products. His background also includes senior finance roles at Mylan, where he helped grow the U.S. sterile injectable market to more than $1 billion in 2018.
Bridseida Cruz has more than 25 years of experience in quality and operations within 503B outsourcing, pharmaceutical, and medical device organizations. She has led FDA warning letter and regulatory observation remediation plans, reduced regulatory risk, and launched a new FDA‑registered compounding facility that improved throughput by 20%. Cruz is a Lean Six Sigma Green Belt and Certified Quality Lead Auditor, underscoring her focus on quality culture and compliance.
Mark L. Baum, Harrow’s Chairman and CEO, said, “I am honored to have Frank and Bridseida join ImprimisRx in these senior leadership roles. At our recent Investor & Analyst Day, I described my vision for Harrow to be the next great U.S. ophthalmic company. ImprimisRx, a trusted national leader in ophthalmic compounding, has become the gold standard innovator, and I am excited to see Frank and Bridseida carry the torch and lead our incredible ImprimisRx team into its next exciting operational phase.”
The leadership change strengthens ImprimisRx’s operational capabilities and positions the subsidiary to support Harrow’s broader strategy of expanding its compounding and branded product portfolio. By bringing in a CEO with a proven track record of scaling businesses and a Head of Quality with deep FDA remediation expertise, Harrow is reinforcing its commitment to safe, effective, and affordable ophthalmic solutions, a core pillar of its growth plan.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.